Base de dados : MEDLINE
Pesquisa : D27.505.954.427.020 [Categoria DeCS]
Referências encontradas : 1276 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 128 ir para página                         

  1 / 1276 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28668395
[Au] Autor:Liu L; Huang C; Bian Y; Miao L
[Ad] Endereço:Clinical Pharmacology Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215006, China. Electronic address: linsheng_liu@126.com.
[Ti] Título:GC-MS based metabolomics of CSF and blood serum: Metabolic phenotype for a rat model of cefoperazone-induced disulfiram-like reaction.
[So] Source:Biochem Biophys Res Commun;490(3):1066-1073, 2017 Aug 26.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cefoperazone is most popularly used in the treatment of complicated infections clinically. Concomitant ingestion of ethnaol and cefoperazone may cause a disulfiram-like reaction. However, very little is known about the possible interactions between cefoperazone treatment and an alcohol with regard to the induction of disulfiram-like reaction. Study of the metabolic impact of cotreatment with cefoperazone and alcohol on animals can facilitate the identification of markers relevant to disulfiram-like reaction. In this study, the serum and cerebrospinal fluid (CSF) metabolites from Sprague-Dawley rats were profiled using gas chromatography mass spectrometry. Serum levels of valine, leucine, glycine, palmitelaidic acid, and 2-hydroxyisobutyrate in combination application group were significantly higher than those in the control; while alanine and pyruvate deceased in cotreatment group. Most TCA intermediates, glutamate and aspartate had lower CSF level in combination application group, except citrate. In addition, most carbohydrates, ethylmalonate and N-acetylaspartate had higher level compared with control group. These results highlight concomitant ingestion of alcohol and cefoperazone generated disulfiram-like reaction by way of disrupting normal metabolic pathway. Cefoperazone magnifes ethanol-induced impairment of TCA cycle and aspartate metabolism, thereby affects energy metabolism and neural transmission.
[Mh] Termos MeSH primário: Dissuasores de Álcool/farmacologia
Consumo de Bebidas Alcoólicas/sangue
Consumo de Bebidas Alcoólicas/líquido cefalorraquidiano
Antibacterianos/farmacologia
Cefoperazona/farmacologia
Dissulfiram/farmacologia
Metaboloma/efeitos dos fármacos
[Mh] Termos MeSH secundário: Consumo de Bebidas Alcoólicas/metabolismo
Animais
Etanol/farmacologia
Cromatografia Gasosa-Espectrometria de Massas/métodos
Masculino
Redes e Vias Metabólicas/efeitos dos fármacos
Metabolômica/métodos
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Anti-Bacterial Agents); 3K9958V90M (Ethanol); 7U75I1278D (Cefoperazone); TR3MLJ1UAI (Disulfiram)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170703
[St] Status:MEDLINE


  2 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28658981
[Au] Autor:Soyka M; Müller CA
[Ad] Endereço:a Department of Psychiatry and Psychotherapy , Ludwig Maximilian University , Munich , Germany.
[Ti] Título:Pharmacotherapy of alcoholism - an update on approved and off-label medications.
[So] Source:Expert Opin Pharmacother;18(12):1187-1199, 2017 Aug.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants. Clinical implications, benefits and risks of treatment are discussed. Expert opinion: Acamprosate, naltrexone, nalmefene and disulfiram are the only approved 'alcohol-specific' drugs. Acamprosate and naltrexone have been evaluated in numerous clinical trials and represent evidence-based treatments in AUDs. Nalmefene use, however, is controversial. Supervised disulfiram is a second-line treatment approach. Compounds developed and licensed for different neuropsychiatric disorders are potential alternatives. Encouraging results have been reported for topiramate, gabapentin and also varenicline, which might be useful in patients with comorbid nicotine dependence. The GABA (γ-aminobutyric acid)-B receptor agonist baclofen has shown mixed results; it is currently licensed for the treatment of AUDs in France only. Gabapentin may be close to approval in the USA. Further studies of these novel treatment approaches in AUDs are needed.
[Mh] Termos MeSH primário: Dissuasores de Álcool/uso terapêutico
Consumo de Bebidas Alcoólicas/tratamento farmacológico
Alcoolismo/tratamento farmacológico
Antidepressivos/uso terapêutico
Antagonistas de Entorpecentes/uso terapêutico
Uso Off-Label
[Mh] Termos MeSH secundário: Alcoolismo/metabolismo
Alcoolismo/psicologia
Seres Humanos
Psicoterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Antidepressive Agents); 0 (Narcotic Antagonists)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1349098


  3 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28538998
[Au] Autor:Lyon J
[Ti] Título:More Treatments on Deck for Alcohol Use Disorder.
[So] Source:JAMA;317(22):2267-2269, 2017 Jun 13.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Dissuasores de Álcool/uso terapêutico
Transtornos Relacionados ao Uso de Álcool/tratamento farmacológico
[Mh] Termos MeSH secundário: Transtornos Relacionados ao Uso de Álcool/epidemiologia
Aminas/uso terapêutico
Baclofeno/uso terapêutico
Ácidos Cicloexanocarboxílicos/uso terapêutico
Citidina Difosfato Colina/uso terapêutico
Dissulfiram/uso terapêutico
Reposicionamento de Medicamentos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Mifepristona/uso terapêutico
Naltrexona/análogos & derivados
Naltrexona/uso terapêutico
National Institute on Alcohol Abuse and Alcoholism (U.S.)
Uso Off-Label
Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos
Taurina/análogos & derivados
Taurina/uso terapêutico
Estados Unidos
Vareniclina/uso terapêutico
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Amines); 0 (Cyclohexanecarboxylic Acids); 0H73WJJ391 (topiramate); 1EQV5MLY3D (Taurine); 30237-26-4 (Fructose); 320T6RNW1F (Mifepristone); 536BQ2JVC7 (Cytidine Diphosphate Choline); 56-12-2 (gamma-Aminobutyric Acid); 5S6W795CQM (Naltrexone); 6CW7F3G59X (gabapentin); H789N3FKE8 (Baclofen); N4K14YGM3J (acamprosate); TOV02TDP9I (nalmefene); TR3MLJ1UAI (Disulfiram); W6HS99O8ZO (Varenicline)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170706
[Lr] Data última revisão:
170706
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4760


  4 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28488530
[Au] Autor:Saissi F; Caflisch C
[Ad] Endereço:1 Sanatorium Kilchberg, Zentrum für Psychosomatik Zürich.
[Ti] Título:CME: Störung durch Alkohol? Vorgehen bei Verdacht auf Alkoholabhängigkeitssyndrom..
[So] Source:Praxis (Bern 1994);106(10):503-510, 2017.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Mh] Termos MeSH primário: Transtornos Relacionados ao Uso de Álcool/diagnóstico
Alcoolismo/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Dissuasores de Álcool/uso terapêutico
Transtornos Relacionados ao Uso de Álcool/sangue
Transtornos Relacionados ao Uso de Álcool/terapia
Alcoolismo/sangue
Alcoolismo/complicações
Alcoolismo/terapia
Assistência Ambulatorial
Biomarcadores/sangue
Diagnóstico Diferencial
Etanol/efeitos adversos
Evolução Fatal
Seres Humanos
Masculino
Insuficiência de Múltiplos Órgãos/diagnóstico
Insuficiência de Múltiplos Órgãos/etiologia
Insuficiência de Múltiplos Órgãos/mortalidade
Admissão do Paciente
Papel do Médico
Atenção Primária à Saúde
Fatores de Risco
Síndrome de Abstinência a Substâncias/sangue
Síndrome de Abstinência a Substâncias/diagnóstico
Síndrome de Abstinência a Substâncias/psicologia
Síndrome de Abstinência a Substâncias/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Biomarkers); 3K9958V90M (Ethanol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170511
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002682


  5 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28220511
[Au] Autor:Goh ET; Morgan MY
[Ad] Endereço:UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK.
[Ti] Título:Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
[So] Source:Aliment Pharmacol Ther;45(7):865-882, 2017 Apr.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The development of alcohol dependence is associated with significant morbidity and mortality. For the majority of affected people the most appropriate goal, in terms of drinking behaviour, is abstinence from alcohol. Psychosocial intervention is the mainstay of the treatment but adjuvant pharmacotherapy is also available and its use recommended. AIM: To provide an updated analysis of current and potential pharmacotherapeutic options for the management of alcohol dependence. In addition, factors predictive of therapeutic outcome, including compliance and pharmacogenetics, and the current barriers to treatment, including doctors' unwillingness to prescribe these agents, will be explored. METHODS: Relevant papers were selected for review following extensive, language- and date-unrestricted, electronic and manual searches of the literature. RESULTS: Acamprosate and naltrexone have a substantial evidence base for overall efficacy, safety and cost-effectiveness while the risks associated with the use of disulfiram are well-known and can be minimised with appropriate patient selection and supervision. Acamprosate can be used safely in patients with liver disease and in those with comorbid mental health issues and co-occurring drug-related problems. A number of other agents are being investigated for potential use for this indication including: baclofen, topiramate and metadoxine. CONCLUSION: Pharmacotherapy for alcohol dependence has been shown to be moderately efficacious with few safety concerns, but it is substantially underutilised. Concerted efforts must be made to remove the barriers to treatment in order to optimise the management of people with this condition.
[Mh] Termos MeSH primário: Dissuasores de Álcool/uso terapêutico
Alcoolismo/tratamento farmacológico
[Mh] Termos MeSH secundário: Alcoolismo/diagnóstico
Alcoolismo/genética
Baclofeno/uso terapêutico
Dissulfiram/uso terapêutico
Combinação de Medicamentos
Frutose/análogos & derivados
Frutose/uso terapêutico
Seres Humanos
Naltrexona/análogos & derivados
Naltrexona/uso terapêutico
Polimorfismo de Nucleotídeo Único
Piridoxina/uso terapêutico
Ácido Pirrolidonocarboxílico/uso terapêutico
Taurina/análogos & derivados
Taurina/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Drug Combinations); 0H73WJJ391 (topiramate); 1EQV5MLY3D (Taurine); 30237-26-4 (Fructose); 5S6W795CQM (Naltrexone); EJQ7M98H5J (metadoxine); H789N3FKE8 (Baclofen); KV2JZ1BI6Z (Pyridoxine); N4K14YGM3J (acamprosate); SZB83O1W42 (Pyrrolidonecarboxylic Acid); TOV02TDP9I (nalmefene); TR3MLJ1UAI (Disulfiram)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.1111/apt.13965


  6 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28182125
[Au] Autor:Wang C; Yang J; Han H; Chen J; Wang Y; Li Q; Wang Y
[Ad] Endereço:Department of Urology, First Hospital of Jilin University; Innovative Drug Research Centre, School of Pharmacy, Chongqing University, Chongqing.
[Ti] Título:Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer.
[So] Source:Int J Nanomedicine;12:827-837, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:In this study, poly(lactic- -glycolic acid) (PLGA) was used as a carrier to construct disulfiram-loaded porous microparticle through the emulsion solvent evaporation method, using ammonium bicarbonate as a porogen. The microparticle possessed highly porous surface, suitable aerodynamic diameter for inhalation (8.31±1.33 µm), favorable drug loading (4.09%±0.11%), and sustained release profile. The antiproliferation effect of release supernatant was detected through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using non-small-cell lung cancer A549 as a model, with only 13.3% of cell viability observed for the release supernatant at 7 days. The antiproliferation mechanism was elucidated to be associated with the enhanced induction of cell apoptosis and cell cycle arrest at S phase through flow cytometry and Western blotting analysis. Finally, wound healing and transwell migration assay showed that they could efficiently inhibit the cell migration. These results demonstrated that disulfiram-loaded porous PLGA microparticle could achieve favorable antitumor efficiency, implying the potential of treating non-small-cell lung cancer in a pulmonary administration.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/patologia
Movimento Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Dissulfiram/farmacologia
Ácido Láctico/química
Neoplasias Pulmonares/patologia
Nanopartículas/química
Ácido Poliglicólico/química
[Mh] Termos MeSH secundário: Administração por Inalação
Dissuasores de Álcool/administração & dosagem
Dissuasores de Álcool/química
Dissuasores de Álcool/farmacologia
Western Blotting
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Dissulfiram/administração & dosagem
Dissulfiram/química
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
Nanopartículas/administração & dosagem
Tamanho da Partícula
Porosidade
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (polylactic acid-polyglycolic acid copolymer); 26009-03-0 (Polyglycolic Acid); 33X04XA5AT (Lactic Acid); TR3MLJ1UAI (Disulfiram)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S121948


  7 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28073872
[Au] Autor:Guillou-Landreat M; Victorri Vigneau C; Gerardin M
[Ad] Endereço:ERCR SPURBO, Department of Addictive Disorders, Université de Bretagne Occidentale, Brest, France.
[Ti] Título:Gambling disorder: a side effect of an off-label prescription of baclofen-literature review.
[So] Source:BMJ Case Rep;2017, 2017 Jan 10.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The use of high-dose baclofen emerged in 2008 in the treatment of alcohol-use disorders. Its prescription is still off-label in France, but recent trials have suggested the interest of using high doses for alcohol dependence, so we have to deal with an increase in its use. However, we still have few data about the adverse effects of a high-dose baclofen prescription, especially in complex addictive disorders. We present a case of a 32-year-old man who sought treatment for gambling disorders (GDs). He had complex addictive disorders, including alcohol-use disorders and GDs. He developed a severe GD, after treatment with a high dose of baclofen. The maximum dose was 160 mg/day, prescribed for his alcohol-use disorders. According to the Naranjo algorithm, the score was +7, it enabled to conclude that problem of gambling was probably imputable to baclofen. We discuss this case with reference to literature.
[Mh] Termos MeSH primário: Dissuasores de Álcool/efeitos adversos
Baclofeno/efeitos adversos
Agonistas dos Receptores de GABA-B/efeitos adversos
Jogo de Azar/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Transtornos Relacionados ao Uso de Álcool/tratamento farmacológico
Diagnóstico Diferencial
Seres Humanos
Masculino
Uso Off-Label
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (GABA-B Receptor Agonists); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE


  8 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28064151
[Au] Autor:Brewer C; Streel E; Skinner M
[Ad] Endereço:The Stapleford Centre, London SW1W 9NP, UK.
[Ti] Título:Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
[So] Source:Alcohol Alcohol;52(2):213-219, 2017 Mar 09.
[Is] ISSN:1464-3502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Disulfiram (DSF) causes the ALDH-mediated deterrence of alcohol consumption. We review recent meta-analyses showing the superior effectiveness of supervised disulfiram (SD) in alcoholism treatment compared with oral naltrexone or acamprosate (ACP). The success of SD is also consistent with the almost complete absence of alcoholism in Japanese homozygotes for 'inefficient' ALDH. However, SD is an underused treatment and some clinicians have ethical objections to DSF. We examine these objections and argue that they are based on a misunderstanding of how DSF works. In particular, we argue that SD is not as is often claimed a variety of aversion therapy but aids cognitive, behavioural, educational and psychosocial interventions. It has some unique features that need to be better understood if it is to be properly compared with other treatments and effectively employed to help alcoholic patients, especially those who have not responded to other evidence-based interventions.
[Mh] Termos MeSH primário: Alcoolismo/tratamento farmacológico
Alcoolismo/psicologia
Temas Bioéticos
Dissulfiram/uso terapêutico
[Mh] Termos MeSH secundário: Dissuasores de Álcool/uso terapêutico
Seres Humanos
Naltrexona/uso terapêutico
Taurina/análogos & derivados
Taurina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Alcohol Deterrents); 1EQV5MLY3D (Taurine); 5S6W795CQM (Naltrexone); N4K14YGM3J (acamprosate); TR3MLJ1UAI (Disulfiram)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170109
[St] Status:MEDLINE
[do] DOI:10.1093/alcalc/agw093


  9 / 1276 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27846399
[Au] Autor:Santos T; Martins Campos A; Morais H
[Ad] Endereço:Neurology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Porto, Portugal. Electronic address: telma.cristiana.santos@gmail.com.
[Ti] Título:Sensory-motor axonal polyneuropathy involving cranial nerves: An uncommon manifestation of disulfiram toxicity.
[So] Source:Clin Neurol Neurosurg;152:12-15, 2017 Jan.
[Is] ISSN:1872-6968
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Disulfiram (tetraethylthiuram disulfide) has been used for the treatment of alcohol dependence. An axonal sensory-motor polyneuropathy with involvement of cranial pairs due to disulfiram is exceedingly rare. The authors report a unique case of an extremely severe axonal polyneuropathy involving cranial nerves that developed within weeks after a regular dosage of 500mg/day disulfiram. To the authors best knowledge, such a severe and rapidly-progressive course has never been described with disulfiram dosages of only 500mg/day.
[Mh] Termos MeSH primário: Dissuasores de Álcool/toxicidade
Alcoolismo/tratamento farmacológico
Nervos Cranianos/efeitos dos fármacos
Dissulfiram/toxicidade
Polineuropatias/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Dissuasores de Álcool/administração & dosagem
Dissulfiram/administração & dosagem
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alcohol Deterrents); TR3MLJ1UAI (Disulfiram)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161116
[St] Status:MEDLINE


  10 / 1276 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27567268
[Au] Autor:Dunn KE; Harrison JA; Leoutsakos JM; Han D; Strain EC
[Ad] Endereço:Department of Psychiatry and Behavioral Sciences, Johns Hopkins, University School of Medicine, Baltimore, MD, USA kdunn9@jhmi.edu.
[Ti] Título:Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.
[So] Source:Alcohol Alcohol;52(1):72-79, 2017 Jan.
[Is] ISSN:1464-3502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: Neither the predictive value of early continuous abstinence in alcohol use disorder (AUD) or the point at which this effect may emerge has been evaluated. This analysis of the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) clinical trial evaluated whether abstinence early in treatment was a predictor of longer term abstinence. METHODS: Participants who stated a goal of total abstinence (N = 954) were dichotomized into Early Abstainer vs. Nonabstainers and were compared on a variety of drinking outcome measures that are frequently used in clinical trial evaluations of alcohol treatment strategies, as a function of duration of early continuous abstinence. RESULTS: Significant differences existed for every outcome. Early Abstinence was significantly associated with fewer drinks per drinking day, number of drinking and number of heavy drinking days, and longer time to first drinking and first heavy drinking day. Effects were evident within the first week. The magnitude of all effects increased as the duration of early abstinence (1-4 weeks) increased, though the size of increase varied across the outcomes. CONCLUSIONS: These data provide evidence that drinking at the beginning of alcohol treatment is significantly and robustly associated with drinking throughout and at the end of a clinical trial treatment for AUD. Early drinking may be a useful early index to identify whether patients are responding positively to a treatment strategy, and provides a useful method for tailoring treatment to patients that is consistent with a personalized medicine approach.
[Mh] Termos MeSH primário: Abstinência de Álcool/tendências
Alcoolismo/diagnóstico
Alcoolismo/terapia
Terapia Comportamental/tendências
Naloxona/administração & dosagem
Taurina/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Abstinência de Álcool/psicologia
Dissuasores de Álcool/administração & dosagem
Alcoolismo/psicologia
Terapia Comportamental/métodos
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Antagonistas de Entorpecentes/administração & dosagem
Taurina/administração & dosagem
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Alcohol Deterrents); 0 (Narcotic Antagonists); 1EQV5MLY3D (Taurine); 36B82AMQ7N (Naloxone); N4K14YGM3J (acamprosate)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160828
[St] Status:MEDLINE
[do] DOI:10.1093/alcalc/agw059



página 1 de 128 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde